Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Jean Bernard Auliac,Maurice Pérol,David Planchard,Isabelle Monnet,Marie Wislez,Hélène Doubre,Florian Guisier,Eric Pichon,Laurent Greillier,Bénédicte Mastroianni,Chantal Decroisette,Roland Schott,Sylvestre Le Moulec,Jennifer Arrondeau,Alexis B. Cortot,Laurence Gerinière,Aldo Renault,Catherine Daniel,Lionel Falchero, Christos Chouaid

Lung Cancer（2019）

引用 36|浏览101

暂无评分

摘要

•Efficacy of osimertinib in real-world setting and in clinical trials was comparable.•Osimertinib was efficient in patients with brain metastasis.•Osimertinib was efficient in second or more lines in T790 M EGFR-mutated patients.•EGFR exon 19 deletion had a better susceptibility to osimertinib.

查看译文

关键词

Non-small cell lung cancer,Tyrosine-kinase inhibitors,T790M EGFR mutation,EGFR-activating mutations,Osimertinib,Early access program

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要